AzTrials
AzTrials

BacteremiaNCT07126106

Prospective Validation of GRADY: A Machine Learning Model for Early Sepsis and Bacteremia Detection in ICU Patients

An observational study of Bacteremia and Sepsis Bacterial, run by Sisli Hamidiye Etfal Training and Research Hospital at 1 site in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to prospectively validate the GRADY prediction models, which use machine learning algorithms to estimate the risk of gram-negative bacteremia and sepsis in intensive care unit (ICU) patients based on routinely collected vital signs and laboratory data. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Bacteremia, Sepsis Bacterial
How many people
55 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Feb 2025to 1 Jan 2026
How long will I take part?
12 Months
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Patients over the age of 18 who are suspected of having bacteremia while being treated in intensive care will be included in the study.

Who may be able to join

  • Patients aged 18 years or older
  • ICU stay of 48 hours or longer
  • Patients from whom blood cultures were obtained during routine monitoring
  • Signed informed consent form

Who cannot join

  • Patients younger than 18 years
  • ICU stay shorter than 48 hours
  • Patients without blood cultures

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

ahmet doğukan bayrak contact

+905453511707

dogukan9653@gmail.com

Turkey (Türkiye)1 site, 1 recruiting
  • Sisli etfal research and training hospital

    Seyrantepe, Istanbul, 34371

    ahmet doğukan bayrak, +905453511707, dogukan9653@gmail.com

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Prospective Validation of the GRADY Bacteremia/Sepsis Prediction Model in Intensive Care Unit Patients: Clinical Performance and Feasibility as an Early Warning System

This study aims to prospectively validate the GRADY prediction models, which use machine learning algorithms to estimate the risk of gram-negative bacteremia and sepsis in intensive care unit (ICU) patients based on routinely collected vital signs and laboratory data. Sepsis, a life-threatening condition associated with high ICU mortality, requires early diagnosis and treatment-yet current diagnostic methods relying on blood cultures are time-consuming. Existing scoring systems such as SOFA, SIRS, and NEWS2 often lack sufficient sensitivity and specificity in early sepsis detection. Unlike traditional tools, the GRADY models seek to provide earlier and more accurate risk stratification. This study will compare the clinical performance of GRADY models against standard scoring systems and explore their integration as early warning tools to support rapid intervention and improve outcomes in critical care.

Read the detailed description

Sepsis is a common and critical clinical syndrome encountered in intensive care units (ICUs), associated with high rates of mortality and morbidity. It is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection (Sepsis-3 definition). Early diagnosis and prompt initiation of appropriate treatment before the onset of organ failure are vital to reducing mortality and morbidity. Gram-negative bacteremia is a significant cause of sepsis cases. Early initiation of appropriate empirical or targeted antibiotic therapy in bacteremia cases plays a pivotal role in patient prognosis. However, the diagnosis of gram-negative bacteremia is generally based on blood culture results, which may take 24-72 hours. The delay during this period is considered a major contributor to increased mortality risk.

In recent years, machine learning-based prediction models have been increasingly used as decision support tools in healthcare. The GRADY prediction models, developed retrospectively in our hospital, aim to predict the risk of sepsis due to gram-negative bacteremia using vital signs and laboratory parameters obtained during routine clinical monitoring. However, prospective validation of these models is essential prior to their integration into clinical practice.

The rationale of this study is to facilitate early identification of ICU patients at risk for bacteremia or sepsis to enable prompt initiation of treatment. Reducing mortality and morbidity through early detection may help alleviate the burden on healthcare systems. Moreover, supporting current clinical practices with early prediction models may enhance decision-making efficiency. The use of early warning systems and machine learning-based algorithms may improve clinical predictive power and allow for timely interventions by clinicians. This study aims to evaluate the diagnostic accuracy and clinical applicability of GRADY models through prospective validation. In this regard, the findings may contribute to the development of new approaches for sepsis and bacteremia management in critical care settings.

In current clinical practice, scoring systems such as the Sequential Organ Failure Assessment (SOFA), Systemic Inflammatory Response Syndrome (SIRS), and National Early Warning Score 2 (NEWS2) are used to define sepsis and to identify high-risk patients early. However, these scoring systems are based on a limited set of clinical and laboratory parameters and have shown suboptimal sensitivity and specificity in early sepsis diagnosis according to various studies. This limitation may reduce the chance of early intervention and negatively affect patient outcomes. GRADY models aim to offer risk prediction based on routinely collected clinical and laboratory data using machine learning algorithms, providing an alternative to conventional scoring systems. This study will compare the diagnostic accuracy and clinical performance of GRADY models with widely used scoring systems such as SOFA, SIRS, and NEWS2.

Currently, there are only a limited number of validated and widely accepted scoring systems available for the early identification of bacteremia. The Pitt Bacteremia Score was developed to predict short-term mortality in patients diagnosed with bacteremia and has been validated in several studies. Unlike the Pitt score, GRADY models aim to predict the risk of bacteremia and sepsis in the early period before diagnosis using routine clinical and laboratory data. Although the two systems do not serve exactly the same purpose, Pitt Bacteremia Scores will be calculated for all patients in this study, and the potential relationship with high-risk classification by the GRADY model will be evaluated statistically.

Keywords
Bloodstream Infection, sepsis, Machine Prediction Methods, external validation
Medical subject headings
Bacteremia, Sepsis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Gram(-) negative bacteremia

    Gram (-) bacteria growth in blood culture

    Measured: 1-28 days

Secondary outcomes (3)
  1. SOFA

    The Sequential Organ Failure Assessment (SOFA) score is a clinical tool that evaluates the extent of a patient's organ dysfunction based on six parameters - respiratory function (PaO₂/FiO₂), coagulation (platelet count), liver function (bilirubin level), cardiovascular status (mean arterial pressure or vasopressor use), central nervous system function (Glasgow Coma Scale), and renal function (creatinine level or urine output) - and it will be assessed at the time of patient admission.

    Measured: it will be assessed at the time of patient admission.

  2. SIRS

    The Systemic Inflammatory Response Syndrome (SIRS) criteria are used to identify a generalized inflammatory state based on four parameters - body temperature, heart rate, respiratory rate or PaCO₂, and white blood cell count

    Measured: they will be assessed at the time of patient admission

  3. NEWS-2

    The National Early Warning Score 2 (NEWS-2) is a clinical scoring system used to assess the severity of a patient's acute illness based on six parameters - respiratory rate, oxygen saturation, systolic blood pressure, heart rate, level of consciousness or new confusion, and temperature

    Measured: it will be assessed at the time of patient admission.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Aug 2025
  2. Study start1 Feb 2025
  3. Primary completion1 Dec 2025 (estimated)
  4. Study completion1 Jan 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
55 participants (estimated)
Target duration
12 Months
IDs, dates and publications
ClinicalTrials.gov ID
NCT07126106
Sponsor's protocol ID
dogu-24
Status last verified
Aug 2025
First submitted
6 Aug 2025
Last updated
17 Aug 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Bacteremia and Sepsis Bacterial, run by Sisli Hamidiye Etfal Training and Research Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact okan derin (+905053580264, okanderin@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Gram(-) negative bacteremia (time frame: 1-28 days). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in